Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of “Buy” from Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has earned a consensus rating of “Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $43.17.

ORKA has been the topic of a number of analyst reports. Wedbush reiterated an “outperform” rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, December 20th.

Oruka Therapeutics Stock Down 2.2 %

Shares of NASDAQ:ORKA opened at $12.19 on Tuesday. The stock has a market capitalization of $426.64 million, a PE ratio of -1.95 and a beta of 0.81. The company’s fifty day moving average is $19.10. Oruka Therapeutics has a 12-month low of $11.95 and a 12-month high of $53.88.

Hedge Funds Weigh In On Oruka Therapeutics

Hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new stake in Oruka Therapeutics during the 4th quarter worth approximately $144,000. Geode Capital Management LLC acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $343,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $1,037,000. Wellington Management Group LLP acquired a new stake in shares of Oruka Therapeutics during the third quarter worth about $2,013,000. Finally, Janus Henderson Group PLC purchased a new position in shares of Oruka Therapeutics during the third quarter worth approximately $5,840,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.